Trade Guardant Health, Inc. - GH CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Trading Conditions
| Long position overnight fee | -0.0225% |
| Short position overnight fee | -0.0219% |
| Overnight fee time | 21:00 (UTC) |
| Min traded quantity | 1 |
| Currency | USD |
| Margin | 20% |
| Stock exchange | United States of America |
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 54.96 |
| Open* | 53.81 |
| Day's Range* | 51.23 - 51.23 |
| 1-Year Change* | -46.86% |
| Volume | N/A |
| Average Vol. (3m) | 25.283 |
| 52 wk Range | N/A |
| Market Cap | 5626.21 |
| P/E Ratio | N/A |
| Shares Outstanding | 102220000 |
| Revenue | 408.13 |
| EPS | -5.41225 |
| Dividend (Yield %) | N/A |
| Beta | 0.80975 |
| Next Earnings Date | Nov 2, 2022 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Aug 16, 2022 | 53.11 | -1.34 | -2.46% | 54.45 | 54.45 | 51.16 |
| Aug 15, 2022 | 54.96 | 1.01 | 1.87% | 53.95 | 56.61 | 53.69 |
| Aug 12, 2022 | 54.10 | 0.83 | 1.56% | 53.27 | 54.83 | 52.69 |
| Aug 11, 2022 | 53.04 | -0.18 | -0.34% | 53.22 | 56.32 | 52.36 |
| Aug 10, 2022 | 52.99 | 2.44 | 4.83% | 50.55 | 53.10 | 49.41 |
| Aug 9, 2022 | 48.87 | -4.69 | -8.76% | 53.56 | 53.56 | 48.47 |
| Aug 8, 2022 | 54.42 | 0.89 | 1.66% | 53.53 | 57.16 | 53.53 |
| Aug 5, 2022 | 52.84 | 5.88 | 12.52% | 46.96 | 52.84 | 45.51 |
| Aug 4, 2022 | 50.91 | -0.37 | -0.72% | 51.28 | 53.39 | 50.89 |
| Aug 3, 2022 | 51.81 | 0.41 | 0.80% | 51.40 | 52.29 | 50.80 |
| Aug 2, 2022 | 50.60 | 3.15 | 6.64% | 47.45 | 51.53 | 47.24 |
| Aug 1, 2022 | 48.27 | -1.03 | -2.09% | 49.30 | 50.33 | 47.44 |
| Jul 29, 2022 | 50.11 | -1.37 | -2.66% | 51.48 | 51.89 | 49.79 |
| Jul 28, 2022 | 51.49 | 1.54 | 3.08% | 49.95 | 52.79 | 49.40 |
| Jul 27, 2022 | 49.91 | 0.92 | 1.88% | 48.99 | 50.54 | 47.43 |
| Jul 26, 2022 | 48.15 | 0.20 | 0.42% | 47.95 | 48.97 | 47.47 |
| Jul 25, 2022 | 49.42 | 1.12 | 2.32% | 48.30 | 49.58 | 47.09 |
| Jul 22, 2022 | 48.38 | -2.17 | -4.29% | 50.55 | 50.73 | 47.29 |
| Jul 21, 2022 | 50.65 | 2.14 | 4.41% | 48.51 | 51.01 | 48.23 |
| Jul 20, 2022 | 48.41 | 1.03 | 2.17% | 47.38 | 49.82 | 46.36 |
Guardant Health, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, November 2, 2022 | ||
| 10:59 | | Q3 2022 Guardant Health Inc Earnings Release |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total revenue | 25.249 | 49.842 | 90.639 | 214.375 | 286.73 | 373.653 |
| Revenue | 25.249 | 49.842 | 90.639 | 214.375 | 286.73 | 373.653 |
| Cost of Revenue, Total | 22.124 | 31.618 | 43.21 | 70.72 | 92.535 | 122.212 |
| Gross Profit | 3.125 | 18.224 | 47.429 | 143.655 | 194.195 | 251.441 |
| Total Operating Expense | 69.096 | 131.529 | 179.331 | 296.746 | 541.68 | 759.654 |
| Selling/General/Admin. Expenses, Total | 36.113 | 69.274 | 89.657 | 139.734 | 299.283 | 398.521 |
| Research & Development | 10.859 | 25.562 | 50.714 | 86.292 | 149.862 | 263.221 |
| Unusual Expense (Income) | 0 | 5.075 | -4.25 | 0 | 0 | -25 |
| Operating Income | -43.847 | -81.687 | -88.692 | -82.371 | -254.95 | -386.001 |
| Interest Income (Expense), Net Non-Operating | -2.285 | -1.468 | 4.415 | 12.56 | 4.905 | 1.353 |
| Other, Net | -0.001 | -0.059 | 0.052 | 0.088 | 4.141 | 0.178 |
| Net Income Before Taxes | -46.133 | -83.214 | -84.225 | -69.723 | -245.904 | -384.47 |
| Net Income After Taxes | -46.139 | -83.221 | -84.263 | -67.851 | -246.283 | -384.77 |
| Net Income Before Extra. Items | -46.139 | -83.221 | -85.063 | -75.651 | -253.783 | -405.67 |
| Net Income | -46.139 | -83.221 | -85.063 | -75.651 | -253.783 | -405.67 |
| Total Adjustments to Net Income | 0 | -5.774 | 0 | 0 | ||
| Income Available to Common Excl. Extra. Items | -46.139 | -88.995 | -85.063 | -75.651 | -253.783 | -405.67 |
| Income Available to Common Incl. Extra. Items | -46.139 | -88.995 | -85.063 | -75.651 | -253.783 | -405.67 |
| Diluted Net Income | -46.139 | -88.995 | -85.063 | -75.651 | -253.783 | -405.67 |
| Diluted Weighted Average Shares | 83.5573 | 83.5573 | 85.8325 | 90.597 | 97.504 | 101.314 |
| Diluted EPS Excluding Extraordinary Items | -0.55218 | -1.06508 | -0.99104 | -0.83503 | -2.6028 | -4.00409 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||||
| Diluted Normalized EPS | -0.55218 | -1.0256 | -1.02322 | -0.83503 | -2.53809 | -4.16448 |
| Total Extraordinary Items | 0 | 0 | 0 | 0 | ||
| Minority Interest | -0.8 | -7.8 | -7.5 | -20.9 | ||
| Other Operating Expenses, Total | 0.7 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total revenue | 78.665 | 92.101 | 94.779 | 108.108 | 96.099 |
| Revenue | 78.665 | 92.101 | 94.779 | 108.108 | 96.099 |
| Cost of Revenue, Total | 28.747 | 29.927 | 30.816 | 33.422 | 31.981 |
| Gross Profit | 49.918 | 62.174 | 63.963 | 74.686 | 64.118 |
| Total Operating Expense | 186.528 | 189.743 | 202.067 | 181.316 | 219.437 |
| Selling/General/Admin. Expenses, Total | 102.273 | 96.092 | 100.283 | 99.873 | 105.699 |
| Research & Development | 55.508 | 63.724 | 70.968 | 73.021 | 81.757 |
| Operating Income | -107.863 | -97.642 | -107.288 | -73.208 | -123.338 |
| Interest Income (Expense), Net Non-Operating | 0.605 | 0.293 | -0.055 | 0.01 | 0.134 |
| Other, Net | 0.01 | -0.143 | -0.087 | 0.898 | -0.048 |
| Net Income Before Taxes | -107.248 | -97.492 | -107.43 | -72.3 | -123.252 |
| Net Income After Taxes | -107.358 | -97.575 | -107.526 | -72.311 | -123.228 |
| Minority Interest | -2.3 | 0 | 0 | -18.6 | 0 |
| Net Income Before Extra. Items | -109.658 | -97.575 | -107.526 | -90.911 | -123.228 |
| Net Income | -109.658 | -97.575 | -107.526 | -90.911 | -123.228 |
| Income Available to Common Excl. Extra. Items | -109.658 | -97.575 | -107.526 | -90.911 | -123.228 |
| Income Available to Common Incl. Extra. Items | -109.658 | -97.575 | -107.526 | -90.911 | -123.228 |
| Diluted Net Income | -109.658 | -97.575 | -107.526 | -90.911 | -123.228 |
| Diluted Weighted Average Shares | 100.955 | 101.172 | 101.42 | 101.704 | 101.853 |
| Diluted EPS Excluding Extraordinary Items | -1.08621 | -0.96445 | -1.06021 | -0.89388 | -1.20986 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -1.08621 | -0.96445 | -1.06021 | -1.05366 | -1.20986 |
| Unusual Expense (Income) | -25 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 103.091 | 242.935 | 468.991 | 597.358 | 1888.36 | 1114.13 |
| Cash and Short Term Investments | 95.256 | 221.32 | 418.961 | 522.802 | 1794.88 | 932.748 |
| Cash & Equivalents | 33.591 | 72.28 | 140.544 | 143.228 | 832.977 | 492.202 |
| Short Term Investments | 61.665 | 149.04 | 278.417 | 379.574 | 961.903 | 440.546 |
| Total Receivables, Net | 3.495 | 12.787 | 35.69 | 47.986 | 53.299 | 97.652 |
| Accounts Receivable - Trade, Net | 3.495 | 12.787 | 35.69 | 47.986 | 53.299 | 97.652 |
| Total Inventory | 2.769 | 7.287 | 9.136 | 15.181 | 22.716 | 30.674 |
| Prepaid Expenses | 1.571 | 1.225 | 5.204 | 11.389 | 17.466 | 53.052 |
| Total Assets | 116.565 | 342.938 | 587.403 | 962.535 | 2271.78 | 2204.5 |
| Property/Plant/Equipment, Total - Net | 12.634 | 16.036 | 31.003 | 72.808 | 100.125 | 313.904 |
| Property/Plant/Equipment, Total - Gross | 19.12 | 26.732 | 47.637 | 94.731 | 134.47 | 368.728 |
| Accumulated Depreciation, Total | -6.486 | -10.696 | -16.634 | -21.923 | -34.345 | -54.824 |
| Long Term Investments | 0 | 73.254 | 77.563 | 268.783 | 246.597 | 698.034 |
| Other Long Term Assets, Total | 0.84 | 10.713 | 9.846 | 11.772 | 17.253 | 60.938 |
| Total Current Liabilities | 14.278 | 19.627 | 46.944 | 72.734 | 66.809 | 194.687 |
| Accounts Payable | 3.157 | 4.998 | 10.642 | 16.197 | 7.34 | 17.58 |
| Accrued Expenses | 4.012 | 10.412 | 18.597 | 41.21 | 46.285 | 83.558 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.131 | 0.199 | 0.097 | |||
| Other Current Liabilities, Total | 6.978 | 4.018 | 17.608 | 15.327 | 13.184 | 93.549 |
| Total Liabilities | 36.869 | 34.332 | 104.251 | 164.142 | 973.286 | 1559.49 |
| Total Long Term Debt | 16.908 | 0.46 | 0.119 | 0 | 806.292 | 1134.82 |
| Long Term Debt | 16.482 | 0 | 806.292 | 1134.82 | ||
| Capital Lease Obligations | 0.426 | 0.46 | 0.119 | |||
| Other Liabilities, Total | 5.683 | 14.245 | 15.388 | 41.808 | 43.085 | 229.986 |
| Total Equity | 79.696 | 308.606 | 483.152 | 798.393 | 1298.49 | 645.005 |
| Preferred Stock - Non Redeemable, Net | 179.997 | 499.974 | 0 | |||
| Common Stock | 0 | 0 | 0.001 | 0.001 | 0.001 | 0.001 |
| Additional Paid-In Capital | 7.41 | 4.9 | 764.033 | 1150.09 | 1902.39 | 1657.59 |
| Retained Earnings (Accumulated Deficit) | -107.625 | -195.736 | -280.799 | -352.809 | -606.592 | -1007.83 |
| Unrealized Gain (Loss) | -0.086 | -0.532 | -0.083 | 1.111 | 2.697 | -4.764 |
| Total Liabilities & Shareholders’ Equity | 116.565 | 342.938 | 587.403 | 962.535 | 2271.78 | 2204.5 |
| Total Common Shares Outstanding | 83.5573 | 83.5573 | 85.8325 | 94.2614 | 100.214 | 100.214 |
| Other Current Assets, Total | 0.316 | 0 | ||||
| Minority Interest | 41.8 | 49.6 | 57.1 | 0 | ||
| Goodwill, Net | 3.29 | 3.29 | 3.29 | |||
| Intangibles, Net | 8.524 | 16.155 | 14.207 | |||
| Redeemable Preferred Stock | 0 | 0 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 2033.04 | 1891.06 | 1593.41 | 1114.13 | 1113.28 |
| Cash and Short Term Investments | 1940.45 | 1791.66 | 1485.97 | 932.748 | 962.266 |
| Cash & Equivalents | 869.372 | 938.59 | 832.37 | 492.202 | 573.604 |
| Short Term Investments | 1071.08 | 853.072 | 653.601 | 440.546 | 388.662 |
| Total Receivables, Net | 48.039 | 53.667 | 60.744 | 97.652 | 84.331 |
| Accounts Receivable - Trade, Net | 48.039 | 53.667 | 60.744 | 97.652 | 84.331 |
| Total Inventory | 28.876 | 26.494 | 24.739 | 30.674 | 36.613 |
| Prepaid Expenses | 15.679 | 19.236 | 21.958 | 53.052 | 30.07 |
| Total Assets | 2346.74 | 2291.89 | 2225.53 | 2204.5 | 2129.6 |
| Property/Plant/Equipment, Total - Net | 277.436 | 290.695 | 302.592 | 313.904 | 339.929 |
| Property/Plant/Equipment, Total - Gross | 316.255 | 334.966 | 351.876 | 368.728 | 401.411 |
| Accumulated Depreciation, Total | -38.819 | -44.271 | -49.284 | -54.824 | -61.482 |
| Goodwill, Net | 3.29 | 3.29 | 3.29 | 3.29 | 3.29 |
| Intangibles, Net | 15.674 | 15.189 | 14.698 | 14.207 | 13.727 |
| Long Term Investments | 0 | 55.368 | 250.226 | 698.034 | 588.453 |
| Other Long Term Assets, Total | 17.297 | 36.284 | 61.316 | 60.938 | 70.919 |
| Total Current Liabilities | 95.501 | 96.612 | 102.304 | 194.687 | 228.809 |
| Accounts Payable | 22.318 | 21.399 | 15.674 | 17.58 | 32.23 |
| Accrued Expenses | 59.7 | 62.233 | 75.236 | 83.558 | 103.608 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 13.483 | 12.98 | 11.394 | 93.549 | 92.971 |
| Total Liabilities | 1499.69 | 1503.82 | 1516.11 | 1559.49 | 1596.56 |
| Total Long Term Debt | 1132.9 | 1133.54 | 1134.18 | 1134.82 | 1135.46 |
| Long Term Debt | 1132.9 | 1133.54 | 1134.18 | 1134.82 | 1135.46 |
| Minority Interest | 59.4 | 59.4 | 59.4 | 0 | |
| Other Liabilities, Total | 211.895 | 214.269 | 220.23 | 229.986 | 232.286 |
| Total Equity | 847.046 | 788.065 | 709.42 | 645.005 | 533.04 |
| Common Stock | 0.001 | 0.001 | 0 | 0.001 | 0 |
| Additional Paid-In Capital | 1557.95 | 1597.42 | 1626.93 | 1657.59 | 1682.41 |
| Retained Earnings (Accumulated Deficit) | -711.813 | -809.388 | -916.914 | -1007.83 | -1131.05 |
| Unrealized Gain (Loss) | 0.904 | 0.033 | -0.593 | -4.764 | -18.314 |
| Total Liabilities & Shareholders’ Equity | 2346.74 | 2291.89 | 2225.53 | 2204.5 | 2129.6 |
| Total Common Shares Outstanding | 101.086 | 101.265 | 101.623 | 100.214 | 101.896 |
| Other Equity, Total | 0.001 | 0.001 | |||
| Redeemable Preferred Stock | 0 | 0 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Net income/Starting Line | -46.139 | -83.221 | -84.263 | -67.851 | -246.283 | -384.77 |
| Cash From Operating Activities | -36.71 | -72.235 | -72.185 | -47.134 | -103.927 | -209.017 |
| Cash From Operating Activities | 3.693 | 5.206 | 7.136 | 11.411 | 16.065 | 22.271 |
| Non-Cash Items | 3.282 | 10.769 | 6.069 | 15.398 | 173.956 | 193.95 |
| Cash Taxes Paid | 0.014 | 0.026 | 0.102 | 0.298 | 0.331 | 0.393 |
| Cash Interest Paid | 2.243 | 1.339 | 1.251 | 1.181 | 0 | 0 |
| Changes in Working Capital | 2.454 | -4.989 | -1.127 | -6.092 | -47.665 | -40.468 |
| Cash From Investing Activities | 26.202 | -170.416 | -153.028 | -317.57 | -617.086 | -63.155 |
| Capital Expenditures | -1.766 | -6.681 | -20.203 | -21.217 | -54.059 | -75.035 |
| Other Investing Cash Flow Items, Total | 27.968 | -163.735 | -132.825 | -296.353 | -563.027 | 11.88 |
| Cash From Financing Activities | 39.84 | 281.656 | 293.161 | 367.304 | 1410.31 | -66.824 |
| Issuance (Retirement) of Stock, Net | 40.215 | 307.744 | 256.99 | 368.466 | 372.353 | 17.865 |
| Issuance (Retirement) of Debt, Net | -0.375 | -26.088 | -0.443 | -0.128 | 1132.58 | -0.93 |
| Net Change in Cash | 29.332 | 39.005 | 67.948 | 2.684 | 689.749 | -340.689 |
| Financing Cash Flow Items | 36.614 | -1.034 | -94.622 | -83.759 | ||
| Foreign Exchange Effects | 0.084 | 0.455 | -1.693 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -107.358 | -204.933 | -312.459 | -384.77 | -123.228 |
| Cash From Operating Activities | -16.291 | -78.884 | -132.029 | -209.017 | -28.619 |
| Cash From Operating Activities | 5.01 | 10.637 | 16.181 | 22.271 | 7.201 |
| Non-Cash Items | 62.901 | 109.108 | 155.695 | 193.95 | 37.25 |
| Changes in Working Capital | 23.156 | 6.304 | 8.554 | -40.468 | 50.158 |
| Cash From Investing Activities | 123.87 | 250.936 | 203.542 | -63.155 | 110.808 |
| Capital Expenditures | -9.586 | -28.261 | -50.41 | -75.035 | -22.7 |
| Other Investing Cash Flow Items, Total | 133.456 | 279.197 | 253.952 | 11.88 | 133.508 |
| Cash From Financing Activities | -69.953 | -65.044 | -70.604 | -66.824 | -0.012 |
| Financing Cash Flow Items | -73.576 | -74.958 | -82.157 | -83.759 | -0.957 |
| Issuance (Retirement) of Stock, Net | 4.462 | 10.789 | 12.466 | 17.865 | 0.963 |
| Issuance (Retirement) of Debt, Net | -0.839 | -0.875 | -0.913 | -0.93 | -0.018 |
| Foreign Exchange Effects | -1.087 | -1.08 | -1.193 | -1.693 | -0.792 |
| Net Change in Cash | 36.539 | 105.928 | -0.284 | -340.689 | 81.385 |
| Cash Taxes Paid | 0.393 | ||||
| Cash Interest Paid | 0 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group 427000+
Traders
71000+
Active clients monthly
$46000000+
Monthly investing volume
$17000000+
Try now Withdrawn each month
Guardant Health Company profile
About Guardant Health Inc
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood-based tests, data sets and advanced analytics. It has developed its Guardant360, Guardant360 CDx and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. It also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need in Stage II-III colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor Deoxyribonucleic Acid (DNA) in blood. The Company's tests are used by biopharmaceutical companies for a range of applications, including identifying target patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic development.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Guardant Health Inc revenues increased 30% to $373.7M. Net loss increased 60% to $405.7M. Revenues reflect United States segment increase of 33% to $352.6M. Higher net loss reflects Research and development expense increase of 75% to $244.3M (expense), Sales and marketing expense increase of 81% to $176.4M (expense).
| Industry: | Bio Diagnostics & Testing |
3100 Hanover Street
PALO ALTO
CALIFORNIA 94304
US
Income statement
News
Nifty 50 today: overall bullish despite choppy conditions, say analysts
India 50 could continue its bullish outlook unless there are major domestic developments
02:47, 17 August 2022
Berkshire Hathaway ATVI stock buy: Is Buffett betting on Microsoft’s Activision Blizzard acquisition going ahead?
Berkshire Hathaway is gobbling up shares of Activision Blizzard in a display of confidence that Microsoft will will close the deal to purchase Activision Blizzard
00:00, 17 August 2022
Crypto market wrap; Celsius coin keeps falling, Acala burns
Hodlnaut seeks protection from creditors
22:42, 16 August 2022
Crypto market wrap: Acala stablecoin collapses, altcoin prices dip
Investors show no mercy for beleaguered Celsius coin
16:02, 16 August 2022
Nu Holdings stock rises as Brazilian fintech reports rapid Latin America client growth
Nu Holdings (NU), a Brazil-based fintech bank, is disrupting the Latin America finance sector with sleek, modern offerings. Its revenues and customer count are climbing fast and shares jumped by 18% on Tuesday.
15:02, 16 August 2022People Also Watch
Ripple to US Dollar
0.38 Price
| Long position overnight fee | -0.0500% |
| Short position overnight fee | 0.0140% |
| Overnight fee time | 21:00 (UTC) |
| Spread | 0.00660 |
Trade now
Still looking for a broker you can trust?
Join the 427.000+ traders worldwide that chose to trade with Capital.com
